A Perfused In Vitro Human iPSC-Derived Blood–Brain Barrier Faithfully Mimics Transferrin Receptor-Mediated Transcytosis of Therapeutic Antibodies
Open Access
- 12 September 2023
- journal article
- research article
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 43 (8) , 4173-4187
Abstract
Delivering biologics to elicit a therapeutic response in the central nervous system (CNS) remains challenging due to the presence of the blood–brain barrier (BBB). Receptor-mediated transcytosis is a strategy to improve brain exposure after systemic drug administration. The availability of a clinically relevant in vitro BBB model is crucial to investigate transcytosis pathways and to predict the penetration of biologics into the CNS. We created a perfused human in vitro BBB model made of induced pluripotent stem cells (iPSC)-derived brain microvascular endothelial cells (BMEC) for studying transferrin receptor-mediated transcytosis. iPSC-derived BMEC were seeded in the top channel of a three-lane microfluidic device (OrganoPlate®). After 2 days in culture, the established cell model exhibited relevant BBB features, including physiological transendothelial electrical resistance in a transwell setting (1500 Ω*cm2), reduced apparent permeability (Papp) to the fluorescence tracer Lucifer yellow (20-fold less than cell-free chips), expression of key BBB markers such as tight junctions proteins, transporters, receptors and functional P-gp efflux pump. Moreover, the model exhibited functional transferrin receptor-mediated uptake and transcytosis. To assess selective transferrin receptor-mediated transcytosis, a mixture of anti-human transferrin receptor (MEM-189) and control (sheep IgG anti-bovine serum albumin) antibodies was perfused in the top channel for 2 h. The Papp of MEM-189 was 11-fold higher than that of the control antibody, demonstrating facilitated receptor-mediated transcytosis. Compared to published work reporting a 2-fold ratio, this result is remarkable and establishes the suitability of our model for exploring receptor-mediated transcytosis and screening of antibodies for putative brain shuttle application. Graphical Abstract A perfused in vitro human model made of iPSC-derived BMEC with the chief characteristics (barrier tightness, functionality) of the human BBB can be applied to study transferrin receptor (TfR)-mediated transcytosis of therapeutic antibodies. This may bring critical advances in drug shuttle technology. Graphical abstract generated with biorender.com.Keywords
Funding Information
- UCB Pharma
- University of Applied Sciences and Arts Northwestern Switzerland
- FHNW University of Applied Sciences and Arts Northwestern Switzerland
This publication has 34 references indexed in Scilit:
- A novel platform for engineering blood‐brain barrier‐crossing bispecific biologicsThe FASEB Journal, 2014
- A Stable and Reproducible Human Blood-Brain Barrier Model Derived from Hematopoietic Stem CellsPLOS ONE, 2014
- A retinoic acid-enhanced, multicellular human blood-brain barrier model derived from stem cell sourcesScientific Reports, 2014
- Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular ShuttleNeuron, 2014
- Derivation of blood-brain barrier endothelial cells from human pluripotent stem cellsNature Biotechnology, 2012
- IL-7 Promotes T H 1 Development and Serum IL-7 Predicts Clinical Response to Interferon-β in Multiple SclerosisScience Translational Medicine, 2011
- Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis TargetScience Translational Medicine, 2011
- The role of shear stress in Blood-Brain Barrier endothelial physiologyBMC Neuroscience, 2011
- Human astrocytes/astrocyte-conditioned medium and shear stress enhance the barrier properties of human brain microvascular endothelial cellsBrain Research, 2007
- P-Glycoprotein, a gatekeeper in the blood–brain barrierAdvanced Drug Delivery Reviews, 1999